Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric MATCH Subprotocol of LOXO-292 in Tumors With RET Gene Alterations
NCT04320888Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2021
- Primary completion
- Sep 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 3
01
Overview
A Phase 2 trial of selpercatinib in solid tumor, lymphoma, histiocytic disorder, sponsored by National Cancer Institute. Started May 2021; status: active, not recruiting.
02
Drugs
selpercatinib
03
Conditions
solid tumorlymphomahistiocytic disorder
Beyond the preview
Go deeper on NCT04320888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04320888.